Therefore, the increased expression of PD-L1 on tumor cells or infiltrating immune cells after radiotherapy has to be counteracted by blocking the PD-1 pathway, which objectively creates an opportunity for the administration of immunotherapy. The gene discussed is CD274; the disease is neoplasm.